文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

TCL 联合 MHSP65 疫苗接种可诱导小鼠抗肺癌免疫。

Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice.

机构信息

Department of Molecular Biology, Norman Bethune College of Medicine, Jilin University, 130021, Changchun, China.

出版信息

Cancer Immunol Immunother. 2010 Jun;59(6):899-908. doi: 10.1007/s00262-010-0816-2. Epub 2010 Jan 20.

DOI:10.1007/s00262-010-0816-2
PMID:20087582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11030583/
Abstract

To develop effective anti-lung cancer vaccines, we directly mixed mycobacterial heat shock protein 65 (MHSP65) and tumor cell lysate (TCL) from Lewis lung cancer cells in vitro and tested its efficacy on stimulating anti-tumor immunity. Our results showed that MHSP65-TCL immunization significantly inhibited the growth of lung cancer in mice and prolonged the survival of lung cancer bearing mice. In vivo and in vitro data suggest that MHSP65-TCL could induce specific CTL responses and non-specific immunity, both of which could contribute to the tumor inhibition. Thus, this report provides an easy approach to prepare an efficient TCL based tumor vaccine.

摘要

为了开发有效的肺癌疫苗，我们在体外直接混合分枝杆菌热休克蛋白 65（MHSP65）和来自 Lewis 肺癌细胞的肿瘤细胞裂解物（TCL），并测试其刺激抗肿瘤免疫的功效。我们的结果表明，MHSP65-TCL 免疫接种显著抑制了肺癌在小鼠中的生长，并延长了肺癌荷瘤小鼠的生存时间。体内和体外数据表明，MHSP65-TCL 可以诱导特异性 CTL 反应和非特异性免疫，两者都有助于肿瘤抑制。因此，本报告提供了一种制备高效 TCL 基础肿瘤疫苗的简便方法。

相似文献

[1]
Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice.

Cancer Immunol Immunother. 2010-1-20

[2]
Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice.

Int Immunopharmacol. 2018-1-5

[3]
[Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes].

Nan Fang Yi Ke Da Xue Xue Bao. 2013-11

[4]
Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.

Int Immunopharmacol. 2015-7

[5]
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.

Int Immunopharmacol. 2012-5-14

[6]
Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model.

Oncol Rep. 2017-1

[7]
Assessment of in vivo anti-tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms.

Eur J Pharm Sci. 2017-12-24

[8]
Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice.

Vaccine. 2018-11-16

[9]
Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.

BMC Cancer. 2014-1-29

[10]
Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection.

Cell Mol Immunol. 2015-11

引用本文的文献

[1]
Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.

Med Sci Monit. 2019-1-17

[2]
Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in Lewis lung cancer-bearing mice.

Cancer Med. 2018-2-25

[3]
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.

Sci Rep. 2017-10-24

[4]
Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes.

Mol Med Rep. 2014-12

[5]
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.

Hum Vaccin Immunother. 2014

[6]
MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.

Int Immunopharmacol. 2012-5-14

本文引用的文献

[1]
[Immunotherapy for cancer--modern immunologic strategies in oncology].

Dtsch Med Wochenschr. 2008-10

[2]
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

Lancet. 2008-7-12

[3]
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

J Clin Oncol. 2008-2-20

[4]
Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma.

J Clin Endocrinol Metab. 2006-11

[5]
Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.

Eur J Immunol. 2006-5

[6]
Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma.

Biol Pharm Bull. 2006-1

[7]
Chaperone-rich cell lysates, immune activation and tumor vaccination.

Cancer Immunol Immunother. 2006-3

[8]
Targeting the innate immune response with improved vaccine adjuvants.

Nat Med. 2005-4

[9]
CD69 is an immunoregulatory molecule induced following activation.

Trends Immunol. 2005-3

[10]
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

Semin Cancer Biol. 2003-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索